Myelofibrosis Bone Marrow Mononuclear Cells
About:Myelofibrosis Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed myelofibrosis donors. Progressive marrow fibrosis replacing normal hematopoiesis makes marrow biopsy essential for diagnosis and fibrosis grading. Ideal for JAK2/CALR/MPL driver mutation and marrow failure mechanism research. Stratification by fibrosis grade and driver mutation status.
About Myelofibrosis Bone Marrow Mononuclear Cells
Myelofibrosis Bone Marrow Mononuclear Cells for Hematology Research
Myelofibrosis bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with myelofibrosis — a myeloproliferative neoplasm characterized by progressive marrow fibrosis.
Myelofibrosis Biology and Why Bone Marrow
- Myelofibrosis is defined by progressive replacement of normal hematopoietic marrow with fibrotic tissue, driven by clonal hematopoietic stem cells and abnormal megakaryocyte-derived cytokine signaling.
- Bone marrow biopsy is essential for diagnosis and for grading reticulin and collagen fibrosis, a central component of WHO diagnostic criteria that cannot be assessed from peripheral blood.
- Driver mutations in JAK2, CALR, or MPL are present in the majority of cases and are assessed alongside marrow histology for diagnosis and prognostic scoring.
- JAK inhibitor therapy (e.g. ruxolitinib, fedratinib) is the mainstay of symptom management, and marrow-derived material supports pharmacodynamic and resistance research.
- Progressive marrow failure and extramedullary hematopoiesis are hallmark features under active investigation, along with the mechanisms driving transformation to acute leukemia in a subset of patients.
Donor Stratification Available
- Driver mutation status: JAK2, CALR, or MPL
- Marrow fibrosis grade where documented
- Prognostic risk category (e.g. DIPSS) where documented
- Treatment history, including JAK inhibitor exposure or transplant
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed myelofibrosis donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- Myelofibrosis diagnosis confirmation and driver mutation status where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history and fibrosis grade where documented
- Additional myelofibrosis-specific metadata available on request
Applications
- JAK2, CALR, and MPL driver mutation studies
- JAK inhibitor pharmacodynamic and resistance research
- Marrow fibrosis mechanism and progression studies
- Extramedullary hematopoiesis research
- Leukemic transformation biomarker studies
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection, and our MPN BMMCs for broader myeloproliferative neoplasm studies.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Myelofibrosis BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.